Galapagos (NASDAQ:GLPG) Reaches New 1-Year Low at $28.18

Galapagos NV (NASDAQ:GLPGGet Free Report) shares hit a new 52-week low on Wednesday . The company traded as low as $28.18 and last traded at $28.20, with a volume of 10370 shares changing hands. The stock had previously closed at $28.38.

Analyst Upgrades and Downgrades

GLPG has been the subject of a number of research reports. StockNews.com downgraded shares of Galapagos from a “buy” rating to a “hold” rating in a research report on Monday, March 18th. Morgan Stanley reissued an “equal weight” rating and issued a $38.00 price objective on shares of Galapagos in a research note on Monday, April 22nd. Finally, Bank of America restated an “underperform” rating and set a $31.00 target price (down previously from $41.00) on shares of Galapagos in a research report on Thursday, March 28th. One equities research analyst has rated the stock with a sell rating and four have given a hold rating to the company’s stock. According to MarketBeat, Galapagos currently has an average rating of “Hold” and a consensus target price of $34.50.

View Our Latest Stock Analysis on GLPG

Galapagos Trading Down 0.4 %

The company has a fifty day moving average of $30.64 and a 200 day moving average of $35.61.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. FMR LLC boosted its position in Galapagos by 0.7% during the third quarter. FMR LLC now owns 4,317,676 shares of the biotechnology company’s stock valued at $149,176,000 after purchasing an additional 28,497 shares during the last quarter. Stonepine Capital Management LLC boosted its holdings in Galapagos by 17.6% during the third quarter. Stonepine Capital Management LLC now owns 802,544 shares of the biotechnology company’s stock valued at $27,728,000 after acquiring an additional 119,880 shares during the period. Primecap Management Co. CA boosted its holdings in Galapagos by 1.4% during the fourth quarter. Primecap Management Co. CA now owns 678,877 shares of the biotechnology company’s stock valued at $27,596,000 after acquiring an additional 9,200 shares during the period. Wellington Management Group LLP lifted its stake in shares of Galapagos by 3.9% in the fourth quarter. Wellington Management Group LLP now owns 495,217 shares of the biotechnology company’s stock valued at $20,131,000 after buying an additional 18,552 shares during the period. Finally, Hudson Bay Capital Management LP lifted its stake in shares of Galapagos by 7.7% in the third quarter. Hudson Bay Capital Management LP now owns 350,000 shares of the biotechnology company’s stock valued at $12,092,000 after buying an additional 25,000 shares during the period. Institutional investors and hedge funds own 32.46% of the company’s stock.

Galapagos Company Profile

(Get Free Report)

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.

Further Reading

Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.